multiple

Sanofi's new multiple sclerosis drug suffered a setback, with its stock price falling more than 4% in pre-market trading.

① Sanofi ① The experimental drug tolebrutinib failed to meet its primary endpoint in a late-stage clinical trial for th...

Stock
2026-01-12
Popular in
  1. Alibaba's stock price surges on AI narrative; spot silver hi

    Stock
  2. What will be the next phase of the AI ​​race? OpenAI calls on th

    Stock
  3. Is Nvidia's dominant position in jeopardy? Morgan Stanley st

    Stock
  4. AI bubble theory resurfaces; Google looms large, what will becom

    Stock